Treatment of HPV Infection in Perimenopausal and Postmenopausal Women

Inclusion Criteria: The age of 45-65 years (inclusive); HPV test indicates positive cervical and vaginal high-risk HPV; Cervical HSIL was excluded according to the 2015 US Transitional Clinical Guidelines for Cervical Cancer Screening. Patients with high-grade cervical intraepithelial lesions, who have undergone cervical conotomy or have undergone total or subtotal hysterectomy in the past, and HPV tests indicate high-risk cervical and vaginal HPV infection; If the combination of clear vaginal inflammation, symptomatic treatment is needed, then the group test; If the patients were complicated with abnormal uterine bleeding or postmenstrual bleeding, the reproductive system tumor should be excluded and cured, and then the patients were re-enrolled. ⑦ Volunteer to participate in clinical studies and sign informed consent. Exclusion Criteria: Allergic to human interferon alpha 2b vaginal effervescent capsules or prolestrene cream; Pregnant or lactating patients; Patients with abnormal vaginal bleeding without clear cause; ④Patients with cervical high-grade intraepithelial lesions, gynecological malignancies, serious heart, brain, kidney, immune, blood and other systems and psychiatric neuropsychological diseases; ⑤Patients with consciousness disorder and communication disorder can not cooperate with the experiment; ⑥ Patients considered unsuitable or refused to participate in this clinical trial.